Aleniglipron

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

The company set an FDA end-of-Phase-2 meeting for Q2 2026 ahead of a planned Phase 3 start in the second half of the year.